Declan Noone

Declan Noone

Auto-generated profile, based on publicly available information

Declan Noone

European Haemophilia Consortium , Brussels , Belgium

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2013 in Haemophilia
Verified
Journal Article
Closed access
PDF file
BOB. O'Mahony
B. O'Mahony
DND. Noone
D. Noone
PGP. L. F. Giangrande
P. L. F. Giangrande
LPL. Prihodova
L. Prihodova

29 April 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
DNDeclan Noone
Declan Noone
NSNaja Skouw‐Rasmussen
Naja Skouw‐Rasmussen
MLMichelle Lavin
Michelle Lavin
KGKarin P. M. van Galen
Karin P. M. van Galen
RKRezan A. Kadir
Rezan A. Kadir

28 March 2013 in Haemophilia
Verified
Journal Article
Closed access
PDF file
AFAlbert Farrugia
Albert Farrugia
JCJ. Cassar
J. Cassar
MKM. C. Kimber
M. C. Kimber
MBM. Bansal
M. Bansal
KFK. Fischer
K. Fischer
SBS. Balboni
S. Balboni

5 April 2022 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MPMaarten J. Postma
Maarten J. Postma
DNDeclan Noone
Declan Noone
MRMark H. Rozenbaum
Mark H. Rozenbaum
JCJohn Carter
John Carter
MBMarc F. Botteman
Marc F. Botteman
LGLouis Garrison
Louis Garrison
Conventional cost-effectiveness analysis—i.e., assessing pharmaceuticals through a cost per quality-adjusted life year (QALY) framework—originated from a societal commitment to maximize population health given limited resources. This "extra-welfarist" approach has produced pricing and reimbursement systems that are not well- aligned with the unique considerations of orphan drugs. This framework has been slow to evolve along with our increased understanding of the impact of rare diseases, which in turn has complicated the assessment of orphan drugs meant to treat rare diseases. Herein, we (i) discuss the limitations of conventional cost-effectiveness analysis as applied to assessing access to, as well as the pricing and reimbursement of, orphan drugs, (ii) critically appraise alternative and supplemental approaches, and (iii) offer insights on plausible steps forward.

1 September 2020 in Haemophilia
Verified
Journal Article
Closed access
CCChatree Chai-Adisaksopha
Chatree Chai-Adisaksopha
DNDeclan Noone
Declan Noone
RCRandall Curtis
Randall Curtis
NFNeil Frick
Neil Frick
MNMichael B. Nichol
Michael B. Nichol
AIAlfonso Iorio
Alfonso Iorio